Title:
Natural language processing of pathology reports identifies myxofibrosarcoma and dedifferentiated liposarcoma in the VA national database: cohort creation and clinical outcomes

Authors:
Sarah Lindsay, MD1 - lindsays@ohsu.edu
Cecelia Madison, MBI2 - madisonc@ohsu.edu
Kenneth R. Gundle, MD1,2 – gundle@ohsu.edu

Institutions:
1. Department of Orthopaedics & Rehabilitation, Oregon Health & Science University, Portland, OR, USA
2. Clinical Data Science Research Group, Portland VA Medical Center, Portland, OR, USA

Background:
Soft tissue sarcoma (STS) is a rare connective tissue malignancy that comprises less than 1% of all adult tumors. STS describes a diverse group of more than fifty distinct diagnoses. In databases used to identify cancers, STS is often missed or misclassified as a different form of cancer. The rarity of these tumors would make large-scale databases particularly useful for the investigation of clinical outcomes, but relying on International Classification of Diseases (ICD) codes may undercount and misclassify sarcoma diagnoses. The national VA database provides a unique opportunity for STS investigation, due to the availability of all clinical results and reports.

Purposes:
The purpose of this study was to utilize natural language processing (NLP) to analyze pathology reports to identify patients with STS. To test the feasibility of this methodology, we trialed application of NLP to pathology reports to identify myxofibrosarcoma and dedifferentiated liposarcoma. Our hypothesis was that utilizing NLP to analyze pathology reports would identify patients who lack International Classification of Diseases (ICD) codes for STS. Further, we hypothesized that incidence of patients lacking ICD codes for STS would increase in the ICD-10 era. In addition to assessing this novel method of cohort creation, we aimed to determine myxofibrosarcoma and dedifferentiated liposarcoma overall survival in the VA population.

Patients and Methods:
Through the national VA corporate data warehouse, all surgical pathology notes were identified from 2003 through 2022. These reports were retrospectively searched for the diagnosis of “myxofibrosarcoma” and “dedifferentiated liposarcoma.” Patient gender, age at diagnosis, location, and oncologic outcomes were abstracted from the data warehouse to assess survival outcomes and to generate Kaplan Meier curves. A Cox proportional hazards regression analysis was conducted relative hazard ratios. Diagnosis codes were abstracted and the difference in appropriate ICD-9 and ICD-10 coding was compared by Chi-square test.

Results:
In searching 10,684,177 pathology reports, we identified 379 that included the diagnosis “myxofibrosarcoma” and 583 with “dedifferentiated liposarcoma.” Overall, the population was predominately male in both groups (936 of 962, p=0.76). Patients with myxofibrosarcoma had a mean age of 69 (range 30-97, SD 11.8), slightly older than those with differentiated liposarcoma who had a mean age of 67 (range 29-94, SD 11.4, p=0.004).

In patients treated before the VA adopted ICD-10 in October 2010, 82/188 (44%) of myxofibrosarcoma patients and 51/201 (25%) dedifferentiated liposarcoma patients had ICD-9 codes for STS. In the ICD-10 era, both myxofibrosarcoma patients (126/180, 70%, p<0.001) and dedifferentiated liposarcoma patients (165/370, 46%, p<0.001) were more likely to have STS ICD codes compared to the ICD-9 era. For myxofibrosarcoma overall, 264
had an STS diagnosis and 155 (30%) lacked an STS ICD code. In the dedifferentiated liposarcoma group, 265 had an ICD for soft tissue sarcoma, and 318 (55%) had no ICD for STS.

In a Cox proportional hazards regression analysis, myxofibrosarcoma had a hazard ratio of 0.65 (0.50-0.85) for overall survival compared to dedifferentiated liposarcoma (p=0.001). A Kaplan Meier curve confirmed worse 5-year survival probability for dedifferentiated liposarcoma patients compared to myxofibrosarcoma patients (Figure 1, p=0.003).

**Conclusion:**
In the national VA data warehouse, free text searching of pathology reports provided a sensitive way to identify patients with STS and captured patients that would have been missed with ICD codes alone. This cohort confirms decreased overall survival at 5 years of dedifferentiated liposarcoma compared to myxofibrosarcoma, as a marker of convergent validity with prior results. Relying on ICD codes for cohort creation in administrative databases may fail to capture more than a third of all STS, which threatens both internal validity and our overall understanding of disease incidence.

**Level of Evidence:** Diagnostic Study, Level II

**Works Cited:**

**Figure 1: Overall survival of patients with myxofibrosarcoma and dedifferentiated liposarcoma**